Featured Post

Psychedelics Are Advancing in GAD, but None Is Yet Approved

July 16, 2026

Two psychedelics show early GAD trial signals—DT120 and psilocybin—but no agent is approved for anxiety. Interpreting evidence by stage, not label, matters
 Read More

Other top stories

Beyond SSRIs: Why the Next Advance in GAD May Not Target Monoamines

July 7, 2026

Generalized Anxiety Disorder: A Persistent Burden and a New Look at Psychedelics

July 7, 2026

Where Autoantibodies Strike in Anti-NMDAR Encephalitis

January 26, 2026

The latest news on Depression (MDD)

Other stories

Weekly Mind Reader: When Antidepressants Fail

January 23, 2026

How Delusions Take Shape

January 22, 2026

Autistic and Non-Autistic Faces May ‘Speak Different Languages’

January 21, 2026

Yet Another Review Clears Acetaminophen of Autism, ADHD Risk

January 20, 2026

Can AI Close the Global Health Gap?

January 19, 2026

Weekly Mind Reader: Opioid Use in Week One

January 16, 2026

Consensus Report on XT Use in Practice

Read the full report

Subscribe to read
more articles

Subscribe